logo
ResearchBunny Logo
Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Medicine and Health

Open Access Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer

Y. Harada, A. Sato, et al.

This cutting-edge research by Yohei Harada and colleagues reveals the remarkable efficacy of afatinib, a dual inhibitor of HER2 and EGFR, against cancer models featuring the HER2 E401G mutation. Afatinib significantly outperformed traditional treatments, hinting at its potential as a game-changer for patients with this specific mutation.

00:00
00:00
Playback language: English
Citation Metrics
Citations
0
Influential Citations
0
Reference Count
0

Note: The citation metrics presented here have been sourced from Semantic Scholar and OpenAlex.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny